This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


 Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Oct. 25, 2013


Advertisement

Advertisement
 

Advertisement


SOCIETY NEWS


Transplant Surgeons: Meet your ABS MOC requirements through the AJT
American Journal of Transplantation (login required)
Are you having trouble earning the 90 hours of CME required by the ABS MOC Part 2? If so, let the American Journal of Transplantation (AJT) help, with Images in Transplantation, a monthly feature of journal-based CME. Earn 1 AMA PRA Category 1 Credit™ reviewing images illustrating a clinical problem and answering CME questions. Learn more about this CME opportunity here, or click here to submit your paper for consideration.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Abstract deadline Oct. 31 for AST's Cutting Edge of Transplantation 2014
AST
AST presents the Cutting Edge of Transplantation Feb. 13-15, 2014, at the Sheraton Wild Horse Pass in Chandler, Ariz. Submit your basic, clinical or translational abstract related to the CEOT 2014 meeting topic: "Optimizing Long-Term Transplant Survival: Therapeutics, Targets, Technologies." Abstracts will be presented in mini-oral and/or poster format. All abstracts presented at CEOT will receive focused attention and constructive feedback from attendees and faculty. View the preliminary program now to see what will be covered, and check back often as expert faculty are being announced soon. Registration opens in October—don't miss your chance to secure a place at the limited attendance meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Live Webinars: Nov. 19, Dec. 17: CMV consensus and ID guidelines, IPITA conference summary, improving adherence
AST
The Timely Topics in Transplantation webinar series is free to AST members and only $25 per webinar for non-members. Click here to register, members just use your AST username and password during registration to waive the fee!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


TRANSPLANT NEWS


Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry
The Journal of Heart and Lung Transplantation (login required)
Current guidelines recommend intravenous prostacyclin as first-line therapy for patients with pulmonary arterial hypertension in New York Heart Association/World Health Organization functional class (FC) IV, or combination therapy for patients in any FC who do not respond to monotherapy. We investigated the aggressiveness of therapy in patients enrolled in the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry who deteriorated to FC IV or died.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Study: Kidney transplant rejection drugs tied to pregnancy risks
HealthDay News via U.S.
Drugs meant to reduce the risk of organ rejection may increase the risk of miscarriage and birth defects when taken by female kidney transplant patients, according to a new study. The drugs — called mycophenolic acid products — reduce the risk of organ rejection by suppressing the immune system. The study included 163 female transplant patients who discontinued mycophenolic acid products prior to conception and 114 who conceived while taking the anti-rejection drugs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement


Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit astellas.us
Advertisement
University of Vermont Transplant Nephrologist

The University of Vermont/Fletcher Allen Health Care is seeking applications for a senior faculty member to join the Division of Nephrology. The candidate should be UNOS certified in kidney and pancreas transplants, experienced in educating nephrology fellows, growing transplant programs, and providing administrative leadership. Apply Here
Amnis
The FlowSight offers high performance in a small package. Its innovative design increases signal and minimizes noise to provide unmatched fluorescence sensitivity. Twelve standard detection channels simultaneously produce brightfield, darkfield and up to ten channels of fluorescence imagery of every cell. More info


Extended criteria donor lungs and clinical outcome: Results of an alternative allocation algorithm
The Journal of Heart and Lung Transplantation (login required)
Despite the scarcity of donor lungs, most potential donor organs are not offered by organ procurement organizations or are turned down by transplant centers because no suitable recipient is found according to regular allocation. Although extended criteria donors (ECDs) have recently been considered by many programs, the lung utilization rate remains less than 30 percent in most countries. The allocation policy of Eurotransplant for donor lungs that have been turned down for donor-related medical reasons by three centers is to attempt a rescue offer, for which centers choose the recipients themselves. At Hannover Medical School we systematically divert these organs to more stable recipients to avoid adverse transplant outcomes. We follow up on these transplants and compare them with those following regular allocation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Diagnose faster, when it matters most.
For nearly 30 years, physicians have trusted Viracor-IBT Laboratories to provide accelerated results, specialized expertise and exceptional service in transplant testing. Learn more at www.viracoribt.com.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection
Transplantation
Urinary tract infection (UTI) is a frequent, serious complication in kidney allograft recipients. We reviewed the records of 1166 kidney allograft recipients who received their allografts at our institution between January 2005 and December 2010 and determined the incidence of UTI during the first 3 months after transplantation (early UTI). We used Cox proportional hazards models to determine the risk factors for early UTI and whether early UTI was an independent risk factor for subsequent bacteremia or acute cellular rejection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Research: Old cancer drug may help prevent rejection after transplantation
By Joy Burgess
According to new transplant research in Sweden, an old cancer drug, Zebularine, may help to prevent rejection after transplantation. Rejection of the new tissue or organ has long been a problem for patients after receiving a transplant from an organ donor. However, this new discovery may help scientists to develop new anti-rejection treatments that will provide excellent results for transplant patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Heart transplantation outcomes from cardiac arrest–resuscitated donors
The Journal of Heart and Lung Transplantation (login required)
The aim of this study was to compare the outcomes of heart transplantation from cardiopulmonary-resuscitated donors (CPR+) to those who received hearts from donors who did not require cardiopulmonary resuscitation (CPR−). This large, multicenter adult heart transplant database from across the USA did not show inferior outcomes in recipients of heart transplantation from selected CPR+ donors. Recipient and graft survival were similar over five years of follow-up.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Acute hepatitis and liver failure following the use of a dietary supplement Intended for weight loss or muscle building (CDC)
Widely pescribed satin could help organ-transplant patients (Scientific American)
World first: Lungs awaiting transplant preserved 11 hours outside body (Medical Xpress)
Antiviral treatment for hepatitis B virus recurrence following liver transplantation (Clinical Transplantation)
Young transplant patients 'at higher risk of kidney disease' (MedicalNews Today)

Don't be left behind. Click here to see what else you missed.




Groundbreaking trachea transplant could become routine
ABC
The first person to breathe through a tissue-engineered windpipe is still alive today, raising hopes that the science fiction-style transplant could one day become routine. The unnamed Colombian mother of two was 30 years old when she signed on to swap her tuberculosis-ravaged trachea for a stem cell-seeded donor organ. Now, five years later, the woman leads a "normal" life. "These results confirm what we -- and many patients -- hoped at the time of the original operation: that tissue-engineered transplants are safe and effective in the long term," Dr. Paolo Macchiarini, the Stockholm-based surgeon who pioneered the procedure, said in a statement.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin
Transplantation
The sensitivity of fasting plasma glucose in screening for new-onset diabetes after transplantation has been questioned, particularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7-8 hours after administration. Oral glucose tolerance testing has been mooted as an alternative but is inconvenient for patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Oct. 19, 2013
Oct. 11, 2013
Oct. 4, 2013
Sept. 27, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063